warning about possible hepatic failure with Serzone

January 2002

The FDA is now warning about possible hepatic failure with Serzone. In fact, you'll see a new "black-box" warning in the package insert.

The incidence of hepatic failure is very rare...one case for every 250,000 to 300,000 patients using Serzone (nefazodone) for one year.

But this rate is about 4 times higher than expected.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote